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INTRODUCTION
Tumor growth and the development of
hematologic metastases depend on angio-
genesis, and the inhibition of this process
represents a target for therapy (1). Several
endothelial receptor tyrosine kinases
(RTKs) play key roles in coordinating vas-
cular proliferation, differentiation, and
maintenance/integrity (2,3). These in-
clude the vascular endothelial growth fac-
tor (VEGF) family of receptors (Flt-1, Flt-4,
and KDR/Flk-1) and Tie (Tie-1 and Tie-2/
Tek) RTKs (2,3). The Tie receptors are es-
sential for embryonic development, and
targeted disruption of the tie genes in
mice highlights their importance in angio-
genesis and vascular remodeling (4). The
angiopoietins (Ang-1 through -4) were
identified as ligands for Tie-2 (3). Tie-1
was recently shown to bind Ang-1 and
Ang-4 and increase its association with
Tie-2 in endothelial cells (5). Proteolytic
cleavage of the Tie-1 ectodomain follow-
ing protein kinase C activation produces a
signaling-competent membrane-bound
truncated Tie-1 receptor (6). As with Tie-2,
the activation of Tie-1 signaling has been
reported to promote endothelial cell sur-
vival through the phosphoinositol-3-
kinase/Akt pathway (7).
In the adult, Tie-1 and Tie-2 are upreg-
ulated in endothelium during both phys-
iological and pathological angiogenesis
(3,8). Increased Tie receptor expression
has been reported in diabetic retinopathy
(9), psoriasis (10), and arthritis (11), in
the vasculature of human tumors includ-
ing brain and breast cancers, and in
melanoma metastases (3,8,12-16). The
soluble extracellular domain of Tie-2 was
reported to act in a dominant-negative
manner to block tumor-stimulated angio-
genesis in the rat cornea and subcuta-
neous window chamber models (17).
Moreover, when delivered systemically,
an adenovirus expressing soluble Tie-2
inhibited the growth of primary murine
tumors and their metastases (18).
Similarly, sTie-1 or anti–Tie-1 antibodies
have been shown to inhibit the growth of
tumors by disrupting the tumor neovas-
culature.
Various therapeutic approaches are
being investigated to inhibit pathologi-
cal angiogenesis, including the use of
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at E-1, but not E-2, specifically inhibited tie-1 promoter activity by up to 75% compared with control oligonucleotides in en-
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blocking antibodies, small molecule in-
hibitors, antisense oligonucleotides, and
ribozymes (1). A novel alternative strat-
egy is to employ anti-gene approaches
to inhibit the expression of angiogenesis-
associated genes. To test this paradigm,
we are using triple helical (triplex)
DNA formation, which relies on the
sequence-specific binding of oligonu-
cleotides to duplex DNA (19,20), to
validate targets in the endothelial-
restricted RTK genes. The ideal triplex
DNA target is a homopurine-
homopyrimidine sequence that allows
the triplex-forming oligonucleotide
(TFO) to bind in the major groove of
double-stranded DNA, forming
Hoogsteen hydrogen bonds with the
purine strand (reviewed in 21-23).
Triplex DNA formation represents a
promising approach to selectively in-
hibit gene expression. It offers potential
advantages over the use of antisense
oligonucleotides and ribozymes, as gen-
erally only two sequences (alleles) need
to be blocked per cell to prevent the
generation of all RNA species arising
from the target gene (21,22). TFO can be
directed to inhibit gene expression by
competing with the binding of activat-
ing transcription factors to regulatory
sites or by disrupting transcriptional
elongation (21-32). Advances in this ap-
proach have been achieved through the
development of oligonucleotide analogs
such as N3′ → P5′ phosphoramidates
(28), peptide nucleic acid (PNA) (33),
and 2′-aminoethoxy–substituted riboses
(30) that are resistant to intra- and
extracellular nucleases and form strong
DNA triplexes (21-23). Whereas the
close association of condensed DNA
with chromatin can serve as a barrier to
DNA triplex formation, this does not
appear to present a problem when tar-
geting transcriptionally active regions
of DNA (21). Indeed, triplex DNA for-
mation has been successfully targeted
to inhibit endogenous gene expression
(28). The recent demonstration of
triplex-mediated gene modification in a
murine model represents a major step
toward the use of TFO for gene-based
therapies (34). In addition, the current
development of novel sequence-specific
DNA binding agents (35) may provide
alternative agents for the clinical appli-
cation of anti-gene approaches.
We have identified several potential
duplex target sequences in the 5′ regu-
latory regions of the tie genes (36,37),
including three conserved sequences
that encode multiple Ets transcription
factor core (5′-GGAA/T-3′) DNA bind-
ing motifs (38,39). Members of the Ets
family of transcription factors are key
regulators of many genes associated
with differentiation and tissue-specific
and homeostatic processes, including
angiogenesis (38-45). In this study, we
demonstrate that two near-perfect
homopurine-homopyrimidine se-
quences (E-1 and E-2) containing tan-
dem Ets binding sites in the human
tie-1 promoter represent good targets
for triplex DNA formation with purine
motif TFO. By promoter-reporter analy-
sis, we demonstrate that one of these
sequences (E-1) is essential for tie-1 pro-
moter activity in cultured endothelial
cells, and the selective formation of
DNA triplex at the E-1 site leads to sig-
nificant inhibition of tie-1 promoter ac-
tivity in endothelial cells.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotides synthesized with
phosphodiester and phosphorothioate
linkages and HPLC-purified were pur-
chased from MWG-Biotech (Germany).
The sequences of the antiparallel oligo-
nucleotides, T1-ap and T2-ap targeted
to E-1 and E-2, respectively, control
parallel oligonucleotides (T1-P and
T2-P), and together with parallel
pyrimidine motif oligonucleotide,
T1(C/T)-P, are shown in Figure 1.
The duplex sequences used for elec-
trophoretic mobility shift assays
(EMSAs) consist of the E-1 (21 bp)
and E-2 (22 bp) near homopurine-
homopyrimidine targets with three ad-
ditional base pairs of the tie-1 flanking
sequences at each end (Figure 1).
Generation of tie-1 luciferase reporter
constructs
The human tie-1 (~830 bp) gene pro-
moter (37) was cloned into the pGL3
basic luciferase reporter vector
(Promega, WI, USA) (ptie-1luc) as de-
scribed previously (36). In addition, we
cloned a larger 880-bp fragment of the
human tie-1 promoter using an alterna-
Figure 1. Diagram showing the relative positions of the tandem ets transcription factor du-
plex target sequences (E-1 and E-2), SmaI and AccI restriction enzyme sites, and re-
ported transcription start site (arrow) of the human tie-1 promoter (37). The sequences of
the oligonucleotides encoding the E-1 and E-2 target sites that were annealed and used
for electrophoretic mobility shift assays are indicated. The sequences of the antiparallel
(relative to the purine strand of the target DNA sequence) triplex-forming oligonu-
cleotides, T1-ap and T2-ap, targeted against E-1 and E-2, respectively, parallel control
oligonucleotides (T1-p and T2-p), and parallel pyrimidine-rich (T1-(C/T)-p) oligonu-
cleotide are shown.
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tive 3′ PCR primer (5′-TAC TCC AGA
GGC CGA CCC AGG CCA G-3′) under
the conditions described previously
(36). ptie-1luc (830 bp) 5′ deletion con-
structs were generated using the
Erase-a-base system according to the
manufacturer’s instructions (Promega).
Briefly, ptie-1luc was subjected to pro-
gressive exonuclease-III digestion,
blunt ended, religated, and sequenced.
Additional 5′ deletions were generated
by PCR using ptie-1luc as a template.
Specific ptie-1luc Ets binding site
mutants were produced by overlap
PCR using pfu DNA polymerase
(Stratagene, Amsterdam, Netherlands)
under the following conditions: 94 °C
for 30 s, 60 °C for 1 min, and 76 °C for
3 min for 30 cycles. Mutations were in-
troduced into each of the two Ets bind-
ing motifs in E-1 (see Figure 2B) by
PCR using the following primers
(mut-1 sense 5′-AGC CAC CTC ATT
AGC TCT TCC TCC CCA-3′, mut-1
antisense 5′-TGG GGA GGA AGA GCT
AAT GAG GTG GCT-3′; and mut-2
sense 5′-AGC CAC CTC ATT TCC TCT
AGC TCC CCA-3′, mut-2 antisense
5′-TGG GGA GCT AGA GGA AAT
GAG GTG GCT-3′) in combination with
primers flanking the tie-1 promoter se-
quence described previously (36).
Mutant E-1 tie-1 PCR products were
gel-purified and cloned into pCR-
BLUNT (Invitrogen-BV, Netherlands),
restriction-digested with SacI and XbaI,
and subcloned into the SacI and NheI
sites of pGL-3 basic. All DNA plasmids
were prepared using Qiagen maxi-prep
columns (Qiagen, Sussex, UK) and re-
suspended in sterile deionized water.
Plasmid DNA binding assay
Plasmid DNA binding assays were
performed essentially as described by
Vasquez et al. (46). Briefly, TFO (8 pM)
was labeled with 10 μCi [γ32P]dATP
(Amersham Pharmacia Biotech UK,
Bucks, UK) using 10 U T4-polynu-
cleotide kinase (New England Biolabs,
Boston, MA, USA) in a total volume of
10 μL and purified on Chromaspin +
STE-10 columns (Clontech, Basingstoke,
Figure 2. The activity of the two tandem Ets transcription factor core DNA binding sites,
E-1 and E-2, in the human tie-1 promoter. (A) The effect of 5′ deletion on the activity of
tie-1 luciferase reporter constructs (ptie-1luc) in endothelial cells. ptie-1luc constructs
were cotransfected with a CMV promoter–driven Renilla luciferase control (pRL-CMV)
plasmid into bovine aortic endothelial cells (BAECs). After a 72-h expression period,
promoter activity was quantified by dual luciferase assay and normalized to pRL-CMV
activity. Results are the means (± 1 SE, bars) of duplicate samples from six separate ex-
periments (n = 12) expressed as a percentage of the activity of the 830-bp ptie-1luc
construct. (B) Mutations (mut-1 and mut-2) were introduced into the putative ets core
DNA binding motifs (EBS, 5′-GGAA/T-3′) in E-1 by overlap PCR as described in
“Materials and Methods.” The top strand of the E-1 sequence from the human tie-1
promoter is shown. (C) The effect of Ets binding site mutations in E-1 on the activity of
the human tie-1 promoter. Wild-type (tie-1), mutated (mut-1 and mut-2), and reverse
tie-1 control (tie-1rev) luciferase constructs were cotransfected with pRL-CMV into
BAECs. Promoter activity was determined by dual luciferase assay after a 72-h expres-
sion period and represented as a percentage of wild-type 880-bp ptie-1luc plasmid
(tie-1) following normalization to pRL-CMV activity. Results are means (± 1 SE, bars) of
duplicate samples from at least 3 separate experiments (n ≥ 6).
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UK). The ptie-1luc plasmid was restric-
tion-digested with SmaI and AccI (New
England Biolabs), phenol-extracted, eth-
anol-precipitated, and resuspended in
deionized water. The digested plasmid
DNA (~1 μg) was incubated with radio-
labeled TFO (~0.2 pM) in 10 μL binding
buffer (10 mM Tris-HCl, pH 7.6, contain-
ing 10 mM MgCl2 and 10% sucrose) at
37 °C for 16-18 h. Loading buffer (10%
Ficoll and 0.1% bromophenol blue) was
added (2 μL), and the samples were sep-
arated immediately on 1% agarose gels
containing ethidium bromide (EtBr) in
running buffer (90 mM Tris-Borate
buffer, pH 8.0, containing 10 mM MgCl2)
at 65 V for 5 h. The DNA was visualized
under UV light, and the gels were dried
under vacuum at 80 °C on Hybond-N
membrane (Amersham Pharmacia
Biotech UK) and exposed to film.
Electrophoretic mobility shift assays
For EMSAs, we used oligonucleotides
encoding the duplex target sites corre-
sponding to E-1 and E-2 (see Figure 1).
The pyrimidine-rich oligonucleotides
were labeled with [γ32P]dATP, purified
as described above, and annealed with a
1.5-fold excess of the complementary
purine-rich oligonucleotide at 95 °C for
10 min and allowed to cool slowly to
room temperature. Radiolabeled duplex
(2 × 10–9 to 10 × 10–9 M) was incubated
with increasing quantities of TFO (0.01
to 500 pmol) in a total volume of 10 μL
binding buffer for 16 to 18 h at 37 °C.
Loading buffer (2 μL) was added, and
the samples were separated immedi-
ately on 6% nondenaturing polyacry-
lamide gels in running buffer at 100 V
for ~ 2-4 h, dried under vacuum at
80 °C, and exposed to film. The inten-
sity of the bands on the autoradi-
ographs was determined by scanning
densitometry (Image-Pro Plus; Media
Cybernetics, MD, USA). The dissocia-
tion constant (Kd) was estimated by de-
termining the fraction of triplex DNA at
each concentration of TFO and calculat-
ing the midpoint of the titration when
the intensities of the target duplex and
triplex bands were equivalent.
Endothelial cell transfection and dual
luciferase assays
Bovine aortic endothelial cells (BAECs)
were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10%
iron-supplemented calf serum, 25 mM
L-glutamine, 100 U/mL penicillin, and
100 μg/mL streptomycin sulfate (Sigma).
Luciferase reporter constructs were trans-
fected into BAECs at 50% to 60% conflu-
ence on 6-well culture dishes using
ExGen 500 (Euromedex, France) as de-
scribed previously (36). Briefly, ExGen
500 (10 μL) was mixed with 2 μg ptie-1luc
or SV40 promoter control reporter plas-
mid (pSV40luc) (Promega) and 8 ng of
the CMV-driven Renilla luciferase plas-
mid (pRL-CMV) in a total volume of
100 μL serum-free RPMI 1640 for 20 min.
The cells were incubated with the trans-
fection mixture in a total volume of 1 mL
full growth medium at 37 °C. After 6 h,
the medium was replaced and the cells
incubated for a further 72 h and har-
vested and the luciferase activity was de-
termined using the Dual Luciferase Assay
(Promega) as described previously (36).
To examine the activity of TFO on tie-1
promoter activity, various concentrations
of TFO and control oligonucleotides were
incubated with ptie-1luc or pSV40luc in a
total volume of 10 μL binding buffer for
16 to 18 h at 37 °C. Before transfection,
these samples were then mixed with 8 ng
of pRL-CMV and ExGen 500 (10 μL) in a
final volume of 100 μL RPMI 1640 serum-
free medium, incubated for 20 min at
room temperature, and added to BAECs
as described above. Results obtained
from duplicate samples were normalized
to pRL-CMV activity.
RESULTS
Selection of triplex target sites in the
human tie-1 promoter and design of
TFOs
Based on our recent characterization of
the human tie promoters (36) (P.W.H., un-
published data), we have identified sev-
eral purine-rich potential triplex DNA
target sites in these genes. We selected
two sites (E-1 and E-2) in the human tie-1
promoter sequence (37) comprising con-
served tandem Ets binding sites as tar-
gets for our initial investigations (Figure
1). The E-1 homopurine-homopyrimidine
sequence is interrupted by a single T:A
inversion and located between 756 and
796 bp; the E-2 sequence containing one
G:C inversion lies between 505 and 526
bp of the human tie-1 promoter sequence
(37) (GenBank accession no. S79347).
Triplex DNA formation has been de-
scribed using three oligonucleotide motifs
(21,22). Pyrimidine motif (C/T) TFOs
bind in a parallel orientation to the purine
strand of the target duplex to form
C+*G:C (TFO*homopurine:homopyrimi-
dine) and T*AT triplets and require low
pH to facilitate the protonation of cytosine
bases, whereas purine (G/A) motif TFOs
bind in antiparallel orientation to the
purine strand of the target duplex form-
ing G*G:C and A*A:T triplets. Mixed
(G/T) TFOs may bind in either orienta-
tion forming G*G:C and T*AT triplets. We
used purine motif TFOs in preference to
pyrimidine and mixed motif TFOs, as
they form DNA triplex at neutral pH, and
as T residues may promote guanine quar-
tet formation by providing the points for
stable hairpins in G/T TFOs, respectively
(47). We designed specific antiparallel
G/A motif oligonucleotides against E-1
and E-2 (Figure 1) using standard rules of
triplex DNA formation (21,22). To mini-
mize the destabilizing effect of the G:C to
C:G inversion in E-2, we used thymine in
T2-ap, as it is reported to weakly associate
with C:G inversions (T*C:G) in purine
motif TFOs (20,48). However, there is no
natural base that will accommodate a T:A
inversion in the purine motif, so adenine
was used in T1-ap in preference to gua-
nine, as runs of contiguous guanines pro-
mote self-association and the formation of
multimers (20). Oligonucleotides (T1-P
and T2-P) were synthesized in parallel
orientation to the purine-rich strand of
E-1 and E-2 as controls (Figure 1). To im-
prove the resistance of TFOs to intracellu-
lar and extracellular nucleases, we also
generated oligonucleotides with phospho-
rothioate linkages (21,22). As fully phos-
phorothioate-linked oligonucleotides have
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been reported to exhibit reduced target
specificity and triplex DNA formation
(22,49), oligonucleotides were synthesized
with phosphorothioate linkages substi-
tuted for the last three phosphodiester
bonds at the 3′ end.
Activity of the tandem Ets binding
sites in the human tie-1 promoter
The tie-1 promoter contains several Ets
binding sites (36), including the tandem
Ets motifs contained within E-1 and E-2,
and mutation of these Ets motifs in the
murine tie-1 promoter dramatically re-
duces its activity in transgenic mice (50).
Whereas Ets factors have recently been
shown to bind to the E-1 and E-2 Ets sites
(51), the relative contribution of these two
tandem Ets sites to human tie-1 promoter
activity has not been reported. To deter-
mine whether the Ets binding motifs in
E-1 and E-2 are critical for the regulation
of tie-1 and therefore suitable targets for
triplex-mediated gene inhibition, we gen-
erated 5′ deletions of the human tie-1
promoter by progressive exonuclease-III
digestion (Figure 2A) and PCR. The ptie-
1luc human tie-1 promoter–driven firefly
luciferase reporter constructs were tran-
siently transfected into BAECs, and the
activity was measured by dual luciferase
assay (36). The progressive 5′ deletion of
ptie-1luc beyond the E-2 site demon-
strated that this tandem Ets binding site
does not affect tie-1 promoter activity in
cultured endothelial cells, whereas E-1
lies in the minimal promoter region
(Figure 2A). The activity of the E-1 site
was further investigated through the in-
troduction of specific mutations into the
E-1 Ets motifs of ptie-1luc by overlap PCR
(Figure 2B). Mutant E-1 ptie-1luc reporter
activity was reduced to 20% (mut-1) and
60% (mut-2) of wild-type ptie-1luc activ-
ity, demonstrating that these Ets binding
sites are critical for tie-1 regulation
(Figure 2C) and highlighting the potential
of blocking the E-1 site.
Triplex DNA formation with the human
tie-1 promoter
Plasmid binding assays were used as a
rapid method to screen for specific triplex
DNA formation (46). TFO binding was
initially examined against a range of ptie-
1luc and human tie-2 promoter (ptie-2luc)
luciferase reporter plasmid restriction-
fragments (Figure 3A) at a TFO-to-target
DNA ratio of ~1:1 (TFO:DNA duplex).
SmaI digestion of ptie-1luc produces a
770-bp fragment that contains the E-1 and
E-2 sites (Figure 1). Both the antiparallel
oligonucleotides, T1-ap and T2-ap, form
triplex DNA on the 770-bp tie-1 promoter
fragment following overnight incubation
at 37 °C in the presence of 10 mM Mg2+,
which promotes purine motif triplex
Figure 3. Demonstration of specific triplex DNA formation with purine motif oligonu-
cleotides (T1-ap and T2-ap) at the E-1 and E-2 tandem Ets transcription factor binding
sites of the human tie-1 promoter by plasmid DNA binding assay. Plasmids containing the
tie-1 promoter (ptie-1luc) (see Figure 2B) or 900 bp of the human tie-2 promoter (ptie-
2luc) (37) were digested with SmaI alone or in combination with AccI (see Figure 1) and
incubated overnight with radiolabeled oligonucleotides (T1-ap or T2-ap) at 37 °C in the
presence of 10 mM Mg2+. Samples were separated on 1% agarose gels containing ethid-
ium bromide (EtBr) and the DNA visualized under UV light (EtBr gel). The gels were dried
and autoradiographed to detect triplex DNA formation. (A) Triplex DNA formation of the
T1-ap oligonucleotide with intact ptie-1luc plasmid and SmaI or AccI ptie-1luc restriction
fragments containing the E-1 site. No triplex DNA is observed with T1-ap against ptie-2luc
SmaI restriction fragments or with the parallel control oligonucleotide T1-P. (B) Selective
binding of T1-ap only to the 770-bp SmaI ptie-1luc restriction fragment containing wild-
type E-1 sequence, but not the E-1 mutants (mut-1 and mut-2, see Figure 2B). (C) T2-ap
binding to wild-type E-2 present in the same series of wild-type and E-1 mutant (mut-1
and mut-2) SmaI-digested ptie-1luc plasmid fragments. Effect of Mg2+ (D) and K+ (E) ion
concentration on triplex formation with radiolabeled T1-ap and T2-ap.
R E S E A R C H  A R T I C L E
M O L  M E D  1 2 ( 1 - 3 ) 8 - 1 6 ,  J A N U A R Y - M A R C H  2 0 0 6  |  H E W E T T  E T  A L .  |  1 3
formation/stability (20-22). Figure 3A
shows a typical result from these experi-
ments, with triplex DNA formation of
radiolabeled T1-ap against a range of re-
striction-digested tie-1 and tie-2 (ptie-2luc)
promoter plasmids. Selectivity of T1-ap
and T2-ap for the tie-1 promoter was
demonstrated by a lack of triplex DNA
formation with irrelevant plasmid DNA
fragments, including the human tie-2 pro-
moter (ptie-2luc, Figure 3A), which con-
tains a similar multiple Ets binding site
(39,52). No triplex DNA formation was
detected with the control parallel G/A
oligonucleotides (T1-P and T2-P) under
these conditions. To confirm the speci-
ficity of T1-ap and T2-ap, they were incu-
bated with SmaI-digested wild-type and
E-1 mutant ptie-1luc plasmids (Figure 2B).
There was no apparent triplex DNA for-
mation with T1-ap against the ptie-1luc
E-1 mutant (mut-1 and mut-2) SmaI frag-
ments, demonstrating its selectivity for
the E-1 site (Figure 3B). In contrast, the
T2-ap oligonucleotide formed triplex
DNA at the wild-type E-2 site present in
these ptie-1luc SmaI fragments, as ex-
pected (Figure 3C). Similar results were
obtained with a partially phosphoroth-
ioate-linked T1-ap (PSO-T1-ap), which con-
tains three phosphorothioate bonds at the
3′ end.
High Mg2+ ion concentrations increase
the stability of purine motif triplex DNA
by decreasing the repulsion between the
negatively charged TFO and DNA du-
plex (21,22). Reducing the Mg2+ ion con-
centration from 10 mM to ≤1 mM
strongly decreased the amount of triplex
DNA formed by T1-ap and T2-ap TFO in
plasmid binding assays (Figure 4E).
Physiological levels of monovalent ions
generally decrease the formation of DNA
triplex with purine motif TFO by pro-
moting self-association (21,22). As ex-
pected, increasing concentrations of K+
ions decreased T1-ap and T2-ap triplex
DNA formation in the presence of 10
mM Mg2+ (Figure 3D). At physiological
potassium ion concentrations (~150 mM),
however, DNA triplex was still detected
with T1-ap against the 770-bp SmaI frag-
ment of the tie-1 promoter.
The binding characteristics of TFO were
also examined quantitatively by EMSA.
Radiolabeled E-1 or E-2 duplex target
sites (2 × 10–9 to 10 × 10–9 M) were incu-
bated with increasing concentrations of
TFO for 16 to 18 h at 37 °C in binding
buffer and separated on 12% nondenatur-
ing polyacrylamide gels. Typical results of
experiments with T1-ap are shown in
Figure 4. The 27-bp E-1 duplex was
shifted to a distinct, more slowly migrat-
ing triplex band with increasing concen-
trations of T1-ap. The relative amount of
duplex and triplex DNA was determined
from the autoradiographs by scanning
densitometry. The concentration of TFO at
the midpoint of the titration was taken to
be equivalent to the dissociation constant
(Kd). Strong triplex DNA formation was
observed with both T1-ap and T2-ap, with
dissociation constants of 2 × 10–7 to 4 ×
10–7 M determined at physiological pH
and 37 °C. No triplex DNA formation was
observed with the control parallel
oligonucleotides (T1-P and T2-P) at con-
centrations of up to 5 × 10–5 M. The intro-
duction of three phosphorothioate bonds
at the 3′ end of TFO (PSOT1-ap) did not
significantly affect triplex DNA formation:
the Kd of PSOT1-ap was ~3 × 10
–7 M (Figure
4B). With both T1-ap and PSOT1-ap, com-
plete formation of triplex DNA was ob-
served at 1 × 10–6 M in EMSA (Figure 4).
Effect of triplex DNA formation on
ptie-1luc luciferase reporter activity in
endothelial cells
To determine the effect of targeted
triplex formation on the tie-1 promoter,
TFO and control oligonucleotides were in-
cubated with ptie-1luc, or the SV40 viral
promoter-driven firefly luciferase plasmid
pSV40luc as a control, in the presence of
10 mM Mg2+ at 37 °C (16-18 h) to allow
the formation of triplex DNA. The entire
DNA complex was then transfected into
BAECs, and the activity was determined
by dual luciferase assay after a 72-h ex-
pression period. T1-ap resulted in a con-
centration-dependent inhibition of up to
60% of ptie-1luc activity at 20 μm in com-
parison with T1-P–treated controls
(Figure 5A). As predicted from our 5′ dele-
tion study of the tie-1 promoter (Figure
2B), T2-ap, which forms strong triplex
DNA at E-2, did not affect tie-1 promoter
activity (Figure 5A). Tie-1 promoter activ-
ity was also not affected by a parallel
pyrimidine-rich TFO [T1-(C/T)-P] (see
Figure 1) targeted to E-1, which does not
form DNA triplex at neutral pH. When
T2-ap and T1-ap in combination were
preincubated with ptie-1luc, as expected
no further inhibition of tie-1 promoter ac-
tivity was observed (data not shown). The
oligonucleotides had no significant effect
on the pSV40luc control plasmid activity.
Figure 4. Electrophoretic mobility shift assays showing triplex DNA formation at the E-1 tan-
dem Ets binding motif sequence of the human tie-1 promoter. Radiolabeled oligonucleotide
encoding the C/T-rich strand of the tie-1 promoter E-1 site ([32P]-E-1 oligo) was annealed to
the cold complementary G/A strand (see Figure 1), and incubated with increasing concen-
trations of phosphodiester (A) and phosphodiester-phosphorothioate–linked (B) cold T1-ap
(Figure 1), in binding buffer containing 10 mM MgCl and 150 mM KCl.
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It should also be noted that the oligonu-
cleotides did not affect the activity of the
cotransfected CMV promoter–driven
Renilla luciferase control plasmid (pRL-
CMV) used to monitor cell transfection ef-
ficiency, even at ≤ 10,000-fold excess.
The replacement of the last three
3′ phosphodiester bonds with phospho-
rothioate linkages produced oligonu-
cleotides with similar binding character-
istics to those of phosphodiester TFO.
Preformed PSOT1-ap:E-1 DNA triplex led
to a concentration-dependent inhibition
of the activity of ptie-1luc of up to 74% at
25 μM in BAECs in comparison with
PSOT1-P–treated controls (Figure 5B).
DISCUSSION
Triplex DNA formation has been in-
vestigated as a highly selective means of
regulating many clinically relevant tar-
gets such as c-myc (25,31), cyclin D1 (24),
mdr-1 (27), HIV (28), insulin-like growth
factor-1 receptor (29), platelet-derived
growth factor (32), rhodopsin (53), and
the IgE germline gene promoter (30). In
addition to the disruption of transcrip-
tional elongation (21,22,27-29,53), inhibi-
tion of gene expression has been
achieved through triplex DNA formation
at sequences encoding transcription fac-
tor binding sites including SP-1, SRF,
CNBP, PuF, MAZ, Pax5, PU.1, STAT6,
and NF-κB (21,22,24-26,31,32). Here we
demonstrate the ability of antiparallel
purine motif TFOs to selectively form
DNA triplex at two sequences encoding
tandem Ets core DNA binding motifs in
the tie-1 promoter and the triplex-medi-
ated inhibition of promoter activity
through TFO binding to one of these se-
quences (E-1). Although the inhibition of
the IgE germline proximal gene pro-
moter through triplex DNA formation at
a sequence regulated by STAT6, NF-κB,
and the Ets factor PU.1 was reported re-
cently (30), to our knowledge this is the
first demonstration of selective triplex
DNA formation at sequences containing
multiple Ets binding sites.
Ets transcription factors are key regu-
lators of blood vessel growth (40-45).
Tel-1 and Fli-1 have been shown to be
essential for yolk-sac angiogenesis and
maintenance/integrity of the vasculature
beyond embryonic days 11.5 and 12.5,
respectively, in transgenic mice (40,41).
Ets-1 is upregulated in endothelium in
wound healing, inflammation, and the
supporting vasculature of tumors, and in
cultured endothelial cells following stim-
ulation with the highly potent angio-
genic factor, VEGF (43-45). Ets proteins
are important regulators of many
endothelial-restricted genes including
thrombomodulin (54), von Willebrand
factor (55), ICAM-2 (56), vascular en-
dothelial (VE)-cadherin (57), and VEGF
receptor-1 (Flt-1) (58). The murine tie-1
and tie-2 promoters are transactivated by
Ets-1, Ets-2, Elf-1, and Nerf-2 in vitro,
and mutation of the Ets binding motifs
results in reduced tie-1 promoter activity
in mice (50-52). Recently, Elf-1 was
shown to bind the tandem Ets motifs
Figure 5. Selective inhibition of tie-1 promoter activity with the T1-ap triplex-forming oligonu-
cleotide. Tie-1 or SV40 promoter-driven luciferase reporter constructs (ptie-1luc and pSV40luc,
respectively) were incubated with phosphodiester (20 μM) (A) or partial phosphorothioate
(PSO)-modified T1-ap (B), T2-ap and control oligonucleotides (T1-P, T2-P, and T1-(C/T)-P; see
Figure 1) in binding buffer for 18 h and transfected into bovine aortic endothelial cells. After
72 h, reporter activity was determined by dual luciferase assay and normalized to the co-
transfected pRL-CMV control plasmid. Results are means (± 1 SD, bars) of three to five experi-
ments (n = 6-10) expressed as a percentage of the T1-P–treated control reporter plasmid.
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contained in the E-1 and E-2 sequences
(51); however, the relative contribution of
these two sequences to the regulation of
the human tie-1 promoter has not been
reported. Here we demonstrate that the
E-1 Ets binding motifs in the minimal
tie-1 promoter are essential for activity in
vitro, whereas deletion of the E-2 tandem
Ets sites does not affect human tie-1 pro-
moter activity. Moreover, these results
are supported by our findings that only
TFOs (T1-ap) targeted to E-1 inhibit the
activity of the tie-1 promoter in endothe-
lial cells. As similar multiple Ets binding
sites are present in several endothelial
genes, such as Tie-2 (36,52), thrombomod-
ulin (54), ICAM-2 (56), and VE-cadherin
(57), that play key roles in the regulation
of endothelial proliferation, differentia-
tion, and function, this approach may
have broad applicability to cancer and
other pathologies involving endothelial
proliferation/dysfunction.
Antiparallel purine motif TFOs were
used in this study, as they are generally
reported to form triplex DNA with
greater stability than unmodified G/T
and C/T oligonucleotides (22,53) and
do not require low pH (5.0-5.5) to facili-
tate the protonation of cytosines for
triplex DNA formation (21,22). As ex-
pected, reduction of Mg2+ ion concentra-
tion resulted in a loss of triplex DNA
formation/stability. This effect is due to
the reported stabilizing effect of divalent
cations on DNA triplexes through the
neutralization of the repulsive forces be-
tween the negatively charged phospho-
diester backbones of the TFO and target
DNA duplex (21,22,59,60). Conversely,
monovalent ions, and in particular K+,
are inhibitory to triplex DNA forma-
tion/stability with guanine-containing
oligonucleotides. This may reflect the
ability of monovalent ions to coordinate
and stabilize TFO self-association
(through G-quartets and related struc-
tures) or displace divalent cations and
positively charged factors that serve to
stabilize DNA triplex (21,60). Physio-
logical levels of K+ ions (~150 mM) in the
presence of 10 mM Mg2+ resulted in a
strong decrease of triplex DNA forma-
tion. The destabilizing effect of physio-
logical monovalent ion concentrations
may be reduced by the use of oligonu-
cleotide analogs such as N5′ → P3′
phosphoramidates and 2′-aminoethoxy–
substituted riboses that result in posi-
tively charged TFO (28,30,47).
As phosphodiester oligonucleotides
are susceptible to both endo- and exonu-
cleases and subsequently may have a rel-
atively short half-life in cells and tissue
culture medium, we attempted to in-
crease TFO stability by using phospho-
rothioate analogs that are highly resistant
to degradation (61). Phosphorothioate
oligonucleotides have been reported to
produce marked alteration in cellular
function in vitro and in vivo (22,31).
However, the propensity of phospho-
rothioates to bind nonnuclear targets
means that much of their activity may be
due to non–DNA-specific effects, and
they may also exhibit reduced triplex
DNA formation (21,22,49). Indeed, the re-
placement of phosphodiester with phos-
phorothioate bonds resulted in a loss of
specificity of PST1-ap for E-1, and binding
of the control oligonucleotide (PST1-P) to
E-1 was detected at 1 × 10–5 M. Similarly,
we found that phosphorothioate-linked
TFOs and control oligonucleotides
(PST1-ap and PST1-P) nonselectively de-
creased the relative activity of ptie-1luc
and pSV40luc in endothelial cells com-
pared with the activity of the reporter
constructs alone (data not shown).
However, limiting the number of phos-
phorothioate linkages to the last three
3′ bases produced oligonucleotides with
binding characteristics similar to those of
unmodified phosphodiester TFOs and
selectively inhibited tie-1 promoter activ-
ity in endothelial cells (Figures 3-5). Our
results highlight the potential of anti-
gene approaches to specifically modulate
the transcriptional activity of genes regu-
lated by Ets transcription factors, and
may form the basis of an alternative
strategy to inhibit angiogenesis.
ACKNOWLEDGMENTS
We are extremely grateful to Prof.
Malcom Stevens, Cancer Research
Laboratories, Department of Pharmaceu-
tical Sciences, University of Nottingham,
Nottingham, UK, for helpful discussions.
This work is supported by the British
Heart Foundation and the Birmingham
Women’s Hospital NHS Trust.
REFERENCES
1. Talks KL, Harris AL. (2000) The current status of
anti-angiogenic factors. Br. J. Haematol. 109:477-89.
2. Veikkola T, Karkkainen M, Claesson-Welsh L,
Alitalo K. (2000) Regulation of angiogenesis via
vascular endothelial growth factor receptors.
Cancer Res. 60:203-12.
3. Lauren J, Gunji Y, Alitalo K. (1998) Is angiopoi-
etin-2 necessary for the initiation of tumor angio-
genesis? Am. J. Pathol. 153:1333-9.
4. Sato TN et al. (1996) Distinct roles of the receptor
tyrosine kinases Tie-1 and Tie-2 in blood vessel
formation. Nature 376:70-4.
5. Saharinen P et al. (2005) Multiple angiopoietin
recombinant proteins activate the Tie1 receptor
tyrosine kinase and promote its interaction with
Tie2. J. Cell Biol. 169:239-43.
6. Marron MB, Hughes DP, Edge MD, Forder CL,
Brindle NP. (2000) Evidence for heterotypic inter-
action between the receptor tyrosine kinases tie-1
and tie-2. J. Biol. Chem. 275:39741-6.
7. Kontos CD, Cha EH, York JD, Peters KG. (2002)
The endothelial receptor tyrosine kinase Tie1 ac-
tivates phosphatidylinositol 3-kinase and Akt to
inhibit apoptosis. Mol. Cell. Biol. 22:1704-13.
8. Korhonen J et al. (1995) Enhanced expression of
the tie receptor tyrosine kinase in endothelial
cells during neovascularisation. Blood 86:1828-35.
9. Kampfer H, Pfeilschifter J, Frank S. (2001)
Expressional regulation of angiopoietin-1 and -2
and the tie-1 and -2 receptor tyrosine kinases during
cutaneous wound healing: a comparative study of
normal and impaired repair. Lab. Invest. 81:361-73.
10. Kuroda K, Sapadin A, Shoji T, Fleischmajer R,
Lebwohl M. (2001) Altered expression of angio-
poietins and Tie2 endothelium receptor in psoria-
sis. J. Invest. Dermatol. 116:713-20.
11. Uchida T, Nakashima M, Hirota Y, Miyazaki Y,
Tsukazaki T, Shindo H. (2000) Immunohisto-
chemical localisation of protein tyrosine kinase
receptors Tie-1 and Tie-2 in synovial tissue of
rheumatoid arthritis: correlation with angiogene-
sis and synovial proliferation. Ann. Rheum. Dis.
59:607-14.
12. Peters KG et al. (1998) Expression of Tie-2/Tek in
breast tumor vasculature provides a new marker
for evaluation of tumor angiogenesis. Br. J.
Cancer 77:51-6.
13. Stratmann A, Risau W, Plate KH. (1998) Cell
type-specific expression of angiopoietin-1 and
angiopoietin-2 suggests a role in glioblastoma
angiogenesis. Am. J. Pathol. 153:1459-66.
14. Kaipainen A et al. (1994) Enhanced expression of
the Tie receptor tyrosine kinase messenger RNA
in the vascular endothelium of metastatic
melanomas. Cancer Res. 54:6571-7.
1 6 |  H E W E T T  E T  A L .  |  M O L  M E D  1 2 ( 1 - 3 ) 8 - 1 6 ,  J A N U A R Y - M A R C H  2 0 0 6
I N H I B I T I O N  O F  t i e G E N E  E X P R E S S I O N
15. Salven P et al. (1996) Endothelial Tie growth fac-
tor receptor provides antigenic marker for assess-
ment of breast cancer angiogenesis. Br. J. Cancer
74:69-72.
16. Hatva E et al. (1995) Expression of endothelial
cell-specific receptor tyrosine kinases and growth
factors in human brain tumors. Am. J. Pathol.
146:368-78.
17. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS,
Peters K. (1997) Inhibition of tumor angiogenesis
using a soluble receptor establishes a role for
Tie2 in pathologic vascular growth. J. Clin. Invest.
100:2072-8.
18. Lin P et al. (1998) Anti-angiogenic gene therapy
targeting the endothelium-specific receptor tyro-
sine kinase Tie-2. Proc. Natl. Acad. Sci. U. S. A.
95:8829-34.
19. Moser HE, Dervan PB. (1987) Sequence-specific
cleavage of double helical DNA by triple helix
formation. Science 238:645-50.
20. Le Doan T et al. (1987) Sequence-specific recogni-
tion, photocrosslinking and cleavage of the DNA
double helix by an oligo-α-thymidylate cova-
lently linked to an azidoproflavine derivative.
Nucleic Acids Res. 15:7749-60.
21. Chan PP, Glazer PM. (1997) Triplex DNA: funda-
mentals, advances, and potential applications for
gene therapy. J. Mol. Med. 75:267-82.
22. Praseuth D, Guieysse AL, Helene C. (1999) Triple
helix formation and the anti-gene strategy for se-
quence-specific control of gene expression.
Biochim. Biophys. Acta. 1489:181-206.
23. Giovannangeli C, Helene C. (2000) Triplex-forming
molecules for modulation of DNA information
processing. Curr. Opin. Mol. Ther. 2:288-97.
24. Kim HG, Miller DM. (1998) A novel triplex-form-
ing oligonucleotide targeted to human cyclin D1
(bcl-1, proto-oncogene) promoter inhibits tran-
scription in HeLa cells. Biochemistry 37:2666-72.
25. Kim H-G et al. (1998) Inhibition of transcription
of the human c-myc proto-oncogene by intermol-
ecular triplex. Biochemistry 37:2299-304.
26. Neurath MF, Max EE, Strober W. (1995) Pax5
(BSAP) regulates the murine immunoglobulin
3′ alpha enhancer by suppressing binding of
NF-alpha P, a protein that controls heavy chain
transcription. Proc. Natl. Acad. Sci. U. S. A. 90:3501-5.
27. Scaggiante B, Morassutti C, Tolazzi G, Michelutti
A, Baccarani M, Quadrifogloi F. (1994) Effect of
unmodified triple helix-forming oligodeoxyri-
bonucleotide targeted to human multidrug-
resistance gene mdr 1 in MDR cancer cells. FEBS
Lett. 352:380-4.
28. Faria M et al. (2001) Targeted inhibition of tran-
scription elongation in cells mediated by triplex-
forming oligonucleotides. Proc. Natl. Acad. Sci.
U. S. A. 97:3862-7.
29. Rininsland F, Johnson TR, Chernicky CL, Schulze
E, Burfeind P, Ilan J. (1997) Suppression of in-
sulin-like growth factor type I receptor by a
triple-helix strategy inhibits IGF-I transcription
and tumorigenic potential of rat C6 glioblastoma
cells. Proc. Natl. Acad. Sci. U. S. A. 94:5854-9.
30. Stutz AM, Hoeck J, Natt F, Cuenoud B,
Woisetschlager M. (2001) Inhibition of inter-
leukin-4- and CD40-induced IgE germline gene
promoter activity by 2′-aminoethoxy-modified
triplex-forming oligonucleotides. J. Biol. Chem.
276:11759-65.
31. McGuffie EM, Pacheco D, Carbone GM,
Catapano CV. (2000) Antigene and antiprolifera-
tive effects of a c-myc-targeting phosphoroth-
ioate triple helix-forming oligonucleotide in
human leukemia cells. Cancer Res. 60:3790-9.
32. Liu J, Xu R, Jin Y, Wang D. (2001) Triplex targeting
of human PDGF-B (c-sis, proto-oncogene) pro-
moter specifically inhibits factors binding and
PDGF-B transcription. Nucleic Acids Res. 29:783-91.
33. Ray A, Norden B. (2000) Peptide nucleic acid
(PNA): its medical and biotechnical applications
and promise for the future. FASEB J. 14:1041-60.
34. Vasquez KM, Narayanan L, Glazer PM. (2000)
Specific mutations induced by triplex-forming
oligonucleotides in mice. Science 290:530-3.
35. White S, Szewczyk JW, Turner JM, Baird EE,
Dervan PB. (1998) Recognition of the four
Watson-Crick base pairs in the minor groove by
synthetic ligands. Nature 391:468-71.
36. Hewett PW, Daft E, Murray JC. (1998) Cloning
and characterization of the tie-2/tek endothelial
receptor tyrosine kinase promoter. Biochem.
Biophys. Res. Comm. 252:546-51.
37. Korhonen J et al. (1995) Endothelial-specific gene
expression directed by the tie gene promoter in
vivo. Blood 86:1828-35.
38. Laudet V, Hanni C, Stehelin D, Duterque-
Coquillaud M. (1999) Molecular phylogeny of
the ETS gene family. Oncogene 18:1351-9.
39. Graves BJ, Petersen JM. (1998) Specificity within
the ets family of transcription factors. Adv. Cancer
Res. 75:1-55.
40. Lelievre E, Lionneton F, Soncin F, Vandenbunder
B. (2001) The Ets family contains transcriptional
activators and repressors involved in angiogene-
sis. Int. J. Biochem. Cell. Biol. 33:391-407.
41. Wang LC et al. (1997) Yolk sac angiogenic defect
and intra-embryonic apoptosis in mice lacking
the Ets-related factor TEL. EMBO J. 16:4374-83.
42. Hart A et al. (2000) Fli-1 is required for murine
vascular and megakaryocytic development and
is hemizygously deleted in patients with throm-
bocytopenia. Immunity. 13:167-77.
43. Wernert N et al. (1992) c-ets1 proto-oncogene is a
transcription factor expressed in endothelial cells
during tumor vascularization and other forms of
angiogenesis in humans. Am. J. Pathol. 140:119-27.
44. Wernert N et al. (1994) Stromal expression of
c-Ets1 transcription factor correlates with tumor
invasion. Cancer Res. 54:5683-5.
45. Wernert N et al. (2002) The Ets 1 transcription
factor is upregulated during inflammatory angio-
genesis in rheumatoid arthritis. J. Mol. Med.
80:258-66.
46. Vasquez KM, Wensel TG, Hogan ME, Wilson JH.
(1995) High-affinity triple helix formation by
synthetic oligonucleotides at a site within a selec-
table mammalian gene. Biochemistry 34:7243-51.
47. Dagle JM, Weeks DL. (1996) Positively charged
oligonucleotides overcome potassium-mediated
inhibition of triplex DNA formation. Nucleic
Acids Res. 24:2143-9.
48. Beal PA, Dervan PB. (1992) The influence of
single base triplet changes on the stability of a
pur.pur.pyr triple helix determined by affinity
cleaving. Nucleic Acids Res. 20:2773-6.
49. Cogoi S, Rapozzi V, Quadrifoglio F, Xodo L.
(2001) Anti-gene effect in live cells of AG motif
triplex-forming oligonucleotides containing an
increasing number of phosphorothioate linkages.
Biochemistry 40:1135-43.
50. Iljin K et al. (1999) Role of Ets factors in the activ-
ity and endothelial cell specificity of the mouse
Tie gene promoter. FASEB J. 13:377-86.
51. Dube A et al. (2001) Elf-1 is a transcriptional reg-
ulator of the Tie2 gene during vascular develop-
ment. Circ. Res. 88:237-44.
52. Dube A, Akbarali Y, Sato TN, Libermann TA,
Oettgen P. (1999) Role of the Ets transcription
factors in the regulation of the vascular-specific
Tie2 gene. Circ. Res 84:1177-85.
53. Perkins BD, Wilson JH, Wensel TG, Vasquez KM.
(1998) Triplex targets in the human rhodopsin
gene. Biochemistry 37:11315-22.
54. von der Ahe D et al. (1993) Ets transcription fac-
tor binding site is required for positive and
TNFα-induced negative promoter regulation.
Nucleic Acids Res. 21:5636-43.
55. Schwachtgen JL et al. (1997) Ets transcription fac-
tors bind and transactivate the core promoter of
the von Willebrand factor gene. Oncogene
15:3091-102.
56. McLaughlin F, Ludbrook VJ, Kola I, Campbell CJ,
Randi AM. (1999) Characterisation of the tumor
necrosis factor (TNF)-alpha response elements in
the human ICAM-2 promoter. J. Cell Sci.
112:4695-703.
57. Gory S, Dalmon J, Prandini MH, Kortulewski T,
de Launoit Y, Huber P. (1998) Requirement of a
GT box (Sp1 site) and two Ets binding sites for
vascular endothelial cadherin gene transcription.
J. Biol. Chem. 273:6750-5.
58. Wakiya K, Begue K, Stehelin D, Shibuya M.
(1996) A cAMP response element and an Ets
motif are involved in the transcriptional regula-
tion of Flt-1 tyrosine kinase (vascular endothelial
growth factor receptor-1) gene. J. Biol. Chem.
271:30823-8.
59. Blume SW et al. (1999) The integral divalent
cation within the intermolecular
purine*purine. pyrimidine structure: a variable
determinant of the potential for and character-
istics of the triple helical association. Nucleic
Acids Res. 27:695-702.
60. Gamper HB Jr, Kutyavin IV, Rhinehart RL,
Lokhov SG, Reed MW, Meyer RB. (1997)
Modulation of Cm/T, G/A, and G/T triplex sta-
bility by conjugate groups in the presence and
absence of KCl. Biochemistry 36:14816-26.
61. Stein CA, Subasinghe C, Shinozuka K, Cohen JS.
(1988) Physicochemical properties of phospho-
rothioate oligodeoxynucleotides. Nucleic Acids
Res. 16:3209-21.
